New Blood Test Aims to Transform Liver Cancer Surveillance
Posted on 17 Mar 2026
Liver cancer is one of the fastest‑growing causes of cancer‑related death in the U.S., and surveillance programs face gaps in performance and patient adherence that contribute to late diagnoses. Blood‑based tools that improve detection in high‑risk populations and integrate with hepatology workflows are a priority for earlier intervention. In line with this need, preparations are now underway for the U.S. commercial launch of a blood-based liver cancer surveillance test that leverages hepatocyte-specific extracellular vesicles.
Mursla Bio (Cambridge, UK) has been selected for the Association of British HealthTech Industries (ABHI) U.S. Accelerator to support the commercial launch of EvoLiver, the company's U.S. Food and Drug Administration (FDA)-designated liver cancer surveillance test. Mursla Bio focuses on extracellular vesicle science for chronic disease management in at-risk patients. Participation in the accelerator is intended to facilitate U.S. market entry for the assay.
EvoLiver is a blood test intended to improve detection of liver cancer in high‑risk patients. The assay leverages hepatocyte‑specific extracellular vesicle (EV) biology to address limitations of standard surveillance approaches. According to the company, this biology‑driven strategy is aimed at better aligning surveillance with specialist hepatology care pathways.
The ABHI program wil provide access to more than 300 senior healthcare leaders across 35 leading hospitals, 20 health systems, and U.S. insurers, alongside direct operational guidance from Becton Dickinson, Dell Medical School at the University of Texas, and ABHI’s U.S. advisor network. This support is expected to accelerate EvoLiver’s path into clinical workflows and help convert launch readiness into early adoption in specialist hepatology centers. Ongoing U.S. launch preparation includes Clinical Laboratory Improvement Amendments (CLIA) lab readiness, engagement with key opinion leaders and clinical societies, and active dialogue with payors.
The company is pursuing a hepatology‑led, guideline‑aligned commercial strategy, with broader expansion anticipated over time as additional clinical evidence supports wider coverage and adoption. The approach is framed around closing surveillance gaps and improving adherence in populations at risk for hepatocellular carcinoma.
“Bringing a new test into clinical use depends on reaching the right people across the healthcare system,” says Pierre Arsène, founder and chief executive officer of Mursla Bio. “This program strengthens those connections while supporting EvoLiver’s early deployment and laying the commercial foundations for our extracellular vesicle diagnostics platform in the US.”
Related Links
Mursla Bio
